The impact of tramadol and dihydrocodeine treatment on quality of life of patients with cancer pain

International Journal of Clinical Practice

Volumn 64, Issue 12, 2010, Pages 1681-1687

  Leppert, W ^a   Majkowicz, M ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROCODEINE; TRAMADOL;

ADULT; ANALGESIA; ARTICLE; CANCER FATIGUE; CANCER PAIN; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; DYSPNEA; HUMAN; NAUSEA AND VOMITING; PRIORITY JOURNAL; QUALITY OF LIFE; SLEEP DISORDER; VISUAL ANALOG SCALE;

AGED; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; CODEINE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; NEOPLASMS; NOCICEPTIVE PAIN; PAIN MEASUREMENT; PATIENT SATISFACTION; TRAMADOL; TREATMENT OUTCOME;

EID: 78349247073     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02422.x     Document Type: Article

References (25)

1. Hennies MH, Friderichs E, Schneider J,. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 1988; 38: 877-80.
2. Preston KL, Jasinski DR, Testa M,. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 1991; 27: 7-17.
3. Stamer UM, Lehnen K, Höthker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105: 231-8.
4. Schmidt H, Vormfelde SV, Klinder K, et al. Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol 2002; 91: 57-63.
5. Wilder-Smith CH, Hufschmid E, Thormann W,. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor matabolizers. Br J Clin Pharmacol 1998; 45: 575-81.
6. Wilder-Smith CH, Hill L, Spargo K, Kalla A,. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAIDs: a randomized study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001; 91: 23-31.
7. Dobrogowski J, Hilgier M,. Kliniczna ocena dzialania DHC Continus u chorych z bolem przewlekym. Wspolcz Onkol 2003; 7: 528-34.
8. Leppert W, Majkowicz M,. Ocena analgezji i objawow niepozadanych tramadolu i dihydrokodeiny o kontrolowanym uwalnianiu u chorych z bolem nowotworowym-na podstawie zmodyfikowanej skali ESAS. Wspolcz Onkol 2008; 12: 246-54.
9. Mercadante S, Porzio G, Ferrera P, et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006; 31: 242-7.
10. Maltoni M, Scarpi E, Modonesi C, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005; 13: 888-94.
11. Marinangeli F, Cicozzi A, Leonardis M, et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004; 27: 409-16.
12. Porta-Sales J, Gómez-Batiste X, Tuca-Rodriguez A, Madrid-Juan F, Espinosa-Rojas J, Trelis Navarro J,. WHO analgesic ladder-or lift? Eur J Palliat Care 2003; 10: 105-9.
13. Leppert W, Majkowicz M, Luczak J, Wozniak SP,. Ocena jakosci zycia u chorych z bolem nowotworowym leczonych tramadolem i morfina. Psychoonkologia 2002; 6: 1-8.
14. Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA,. High-dose tramadol in comparison to low-dose morphine for cancer pain. J Pain Symptom Manage 1999; 18: 174-9.
15. Leppert W,. Analgesic efficacy and side effects of oral tramadol and morphine administered orally in the treatment of cancer pain. Nowotwory J Oncol 2001; 51: 257-66.
16. Leppert W,. Rola analgetykow opioidowych II stopnia drabiny analgetycznej Swiatowej Organizacji Zdrowia w leczeniu bolu nowotworowego. Onkol Pol 2006; 9: 145-8.
17. Hummel T, Kraetsch H-G, Lötsch J, Hepper M, Liefhold J, Kobal G,. Analgesic effects of dihydrocodeine and tramadol when administered either in the morning or evening. Chronobiol International 1995; 12: 62-72.
18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C 30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Instit 1993; 85: 365-76.
19. Majkowicz M,. Metody pomiaru jakosci zycia stosowane w badaniach wlasnych. In:, De Walden- Galuszko K, Majkowicz M, eds. Jakosc Zycia w Chorobie Nowotworowej. Gdansk: Wydawnictwo Uniwersytetu Gdanskiego, 1994: 78-81.
20. Yalcin I, Aksu F, Bodard S, Chalon S, Belzung C,. Antidepressant-like effect of tramadol in the unpredictable chronic mild stress procedure: possible involvement of the noradrenergic system. Behav Pharmacol 2007; 18: 623-31.
21. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL,. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an atypical opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-85.
22. Barann M, Urban B, Stamer U, Dorner Z, Bönisch H, Brüsch M,. Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol 2006; 531: 54-8.
23. Wilder-Smith CH, Bettiga A,. The analgesic tramadol has minimal effect on gastrointestinal motor function. Br J Clin Pharmacol 1997; 43: 71-5.
24. American Cancer Society. Eastern Cooperative Oncology Group: functional assessment scale. In:, Rubin P, ed. Clinical Oncology: A Functional Approach. New York: American Cancer Society, 1983: 91.
25. Karnofsky DA, Burchenal JH,. The clinical evaluation of chemotherapeutic agents in cancer. In:, MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949: 191-205.